4D Molecular Therapeutics
FDMT
56 hedge funds and large institutions have $400M invested in 4D Molecular Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 31 increasing their positions, 11 reducing their positions, and 18 closing their positions.
182% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 11
4.46% more ownership
Funds ownership: 57.64% → 62.1% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
13% less funds holding
Funds holding: 64 → 56 (-8)
40% less capital invested
Capital invested by funds: $665M → $400M (-$265M)
44% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 18
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$29.8M |
| 2 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$19.7M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
+$13.9M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$9.56M |
| 5 |
BlackRock
New York
|
+$5.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
-$15.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.68M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.65M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$6.83M |
FDMT Hedge Fund Activity: Q2 2021 in Review
56 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q2 2021, worth a combined $400M — down 40% from $665M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of FDMT and 10 opened new positions — a net loss of 8 holders — while 11 trimmed existing stakes and 31 added.
The largest buyer was BVF Inc, adding an estimated $29.8M. The largest seller was SB Management, exiting entirely with an estimated $15.1M sold.
- 56 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q2 2021, down from 64 in Q1 2021.
- Funds reported $400M of 4D Molecular Therapeutics stock for Q2 2021, down 40% quarter-over-quarter.
- 10 funds opened new 4D Molecular Therapeutics positions in Q2 2021 and 18 closed out, a net change of -8 holders.
- The largest 4D Molecular Therapeutics buyer in Q2 2021 was BVF Inc, an estimated $29.8M added.
- The largest 4D Molecular Therapeutics seller in Q2 2021 was SB Management, an estimated $15.1M sold.
Based on aggregated 13F filings for Q2 2021.